夏建川 职务：生物治疗中心主任
职称：教授、医学博士、博士生导师
专长：特别擅长肿瘤的免疫细胞治疗。

主要简介 详细介绍 预约挂号

　　夏建川，教授、医学博士、博士生导师，哈佛大学Dana-Farber肿瘤研究所博士后，享受国务院政府特殊津贴，现任中山大学附属肿瘤医院生物治疗中心主任，体细胞治疗与保健研究中心主任，亚太医学生物免疫学会主任委员，中国细胞治疗质量控制和研究专业委员会主任委员，中国生物治疗临床应用专业委员会副主任委员，中国医药生物技术协会常务理事，中国细胞学会常务理事，广东省细胞生物学学会理事长，广东省抗癌协会生物治疗专业委员会主任委员，国家食品和药品监督管理局新药评审专家，国家华南肿瘤学重点实验室免疫与遗传研究课题组组长。美国《Cancer Letter》杂志编委,《癌症》杂志常务编委，国家自然基金和广东省自然基金重点项目评审专家。
　　夏建川教授 1998年毕业于哈尔滨医科大学，获医学博士学位；1998-2000年在中山大学附属肿瘤医院从事肿瘤学博士后研究工作；2000-2003年在哈佛大学Dana-Farber肿瘤研究所从事肿瘤的免疫治疗和肿瘤疫苗的研究。在此期间，首次证实DC/肿瘤融合细胞疫苗能诱导自发性乳腺癌转基因小鼠产生抗肿瘤免疫应答，为DC/肿瘤融合细胞疫苗在临床治疗肿瘤中的应用奠定了基础，研究成果发表在美国免疫学专业杂志（The Journal of Immunology 2003 and 2004）。2003年12月回国，利用在国外学到的先进分子生物学和肿瘤免疫学技术，积极开展肿瘤病因学和免疫治疗的基础与临床应用研究。在鼻咽癌、肺癌、乳腺癌、胃癌、肠癌、肝癌和肾癌等恶性肿瘤的发病机制，以及肿瘤微环境、肿瘤干细胞、免疫细胞相互作用和免疫细胞治疗的临床应用等方面做出了突破性工作。在国内率先建立了肿瘤体细胞制备技术操作规范、肿瘤体细胞临床应用安全检测标准和体细胞免疫治疗临床应用规范，为我国制定了第一个“自体免疫细胞（T细胞、NK细胞）治疗技术管理规范”,使体细胞免疫治疗向规范道路上迈出了重要的一步，为我国细胞免疫治疗在规范化的基础上开展临床应用做出了重要贡献。主编了国内第一部《肿瘤生物治疗基础与临床应用》 的教材（科学出版社出版），作为国家重点研发项目的首席科学家主持包括国家重点研发项目、国家重大卫生公益事业课题、国家自然科学基金和省部级重大研究项目24项，以第一或通迅作者在高水平收录的科学杂志发表研究论文84篇；包括在Nat Genetics；Clinic Cancer Res；Journal for Immuno Therapy of Cancrer；Journal of Hematology & Oncology；Clinical & translational immunology；The Journal of Immunology和Stem Cells等高水平科学杂志上发表研究论文。作为第一发明人申请发明专利4项，其中授权3项。荣获首届广州新侨留学生回国创业贡献奖。
　　专家门诊时间：每周一的上午，肿瘤的免疫治疗。
　　专业特长：长期从事肿瘤的病因学和肿瘤免疫细胞治疗的基础和临床应用研究。特别擅长肿瘤的免疫细胞治疗。



　　夏建川，教授 医学博士、博士生导师，哈佛大学Dana-Farber肿瘤研究所博士后，享受国务院政府特殊津贴,现任中山大学附属肿瘤医院生物治疗中心主任，体细胞治疗与保健研究中心主任，亚太医学生物免疫学会主任委员，中国细胞治疗质量控制和研究专业委员会主任委员，中国研究型医院学会生物治疗学专业委员会副主任委员，中国生物治疗临床应用专业委员会副主任委员，中国医药生物技术协会常务理事，中国细胞学会常务理事，广东省细胞生物学学会理事长，广东省抗癌协会生物治疗专业委员会主任委员，国家食品和药品监督管理局新药评审专家，国家华南肿瘤学重点实验室免疫与遗传研究课题组组长。美国《Cancer Letter》杂志编委,《癌症》杂志常务编委，国家自然基金和广东省自然基金重点项目评审专家。
　　夏建川 教授 1998年毕业于哈尔滨医科大学，获医学博士学位； 1998-2000年在中山医科大学附属肿瘤医院从事博士后研究工作；2000-2003年在哈佛大学Dana-Farber肿瘤研究所从事肿瘤的免疫治疗和肿瘤疫苗的研究。在此期间，首次证实DC/肿瘤融合细胞疫苗能诱导自发性乳腺癌转基因小鼠产生抗肿瘤免疫应答，为DC/肿瘤融合细胞疫苗在临床治疗肿瘤中的应用奠定了基础，研究成果发表在美国免疫学专业杂志上（J Immunol 2003 Feb 15;170 (4):1980-1986；J Immunol, 2004, 172: 7848-7858；Immunology. 2003 Jun;109(2):300-7），2003年12月回国，利用在国外学到的先进体细胞免疫治疗技术，积极开展肿瘤体细胞免疫治疗的基础和临床应用研究，在国内率先建立了体细胞制备技术操作规范、体细胞临床应用安全检测标准和体细胞免疫治疗临床应用规范，使体细胞免疫治疗向规范道路上迈出了重要的一步，为肿瘤的体细胞免疫治疗在临床治疗过程中安全、有效的应用做出了重要贡献。
　　近年来，主持并参与多项国家和省部级重大临床应用研究项目，积极开展肿瘤病因学和肿瘤体细胞免疫治疗的基础和临床应用研究，在肿瘤病因学和肿瘤体细胞免疫治疗领域发表高水平收入的研究论文80余篇。主编了国内第一部《肿瘤生物治疗基础与临床应用》 的教材（中国科技出版社2011年8月出版）；作为副主编编写了《个体化医学原则》专著（由人民卫生出版社2013年1月出版）；参编了医学高等院校本科教材《临床肿瘤学》和医学高等院校研究生教材《临床肿瘤学》等专著。获得三项国家发明专利（一种人肿瘤细胞分离纯化的技术 国家发明专利号：ZL **.7）；（用于刺激树突状细胞成熟的组合物以及方法 国家发明专利号：ZL 2013 1 **.6)；DC-CIK细胞和抗PD-1抗体组合物及其用途 国家发明专利号ZL 2017 1 **.3）。曾获得省政府科技进步二等奖，2008年首届广州新侨留学生回国创业贡献奖。

主要研究方向
一、医学研究
1、肿瘤的体细胞免疫治疗研究
　　主要致力于体细胞免疫治疗的临床应用研究，包括肿瘤树突状细胞疫苗（DC疫苗），DC/肿瘤融合细胞疫苗、腺相关病毒介导肿瘤抗原转导的DC疫苗（DC-T细胞），细胞因子诱导的杀伤细胞（CIK细胞），DC刺激的CIK细胞（DC－CIK），自然杀伤细胞（NK细胞）和肿瘤浸润性淋巴细胞等。在肿瘤体细胞免疫治疗的临床应用过程中，为了保证临床安全和疗效，制定了体细胞制备流程和临床应用规范化准则，同时经过对大量接受体细胞免疫治疗患者疗效的观察和临床试验研究，建立了多种临床肿瘤体细胞免疫治疗的方案，在肿瘤体细胞免疫治疗的临床应用过程中，为提高体细胞免疫治疗在肿瘤临床中的疗效，经过大量的临床试验研究，在国内提出了肿瘤常规治疗联合体细胞免疫治疗的增效方案，为肿瘤患者在常规治疗（手术、化疗和放疗）后的巩固治疗提供了一种新的治疗手段。并在前期临床试用研究的基础上，率先提出要根据病人的肿瘤特征、遗传背景、病情状况、年龄等制定出适合病人的个体化体细胞免疫治疗策略，并建立了多种临床肿瘤体细胞免疫治疗的具体方案，为体细胞免疫治疗在临床肿瘤治疗中安全、有效的应用起到了关键性作用，真正实现了基础研究的成果向临床应用的快速转化。这些体细胞免疫治疗的具体方案包括：1、对年龄偏大的老年肿瘤患者采取少量抽血多次回输的方案，对抑制肿瘤的复发和转移取得了较好效果；2、率先提出在化疗或放疗间隙过程中联合体细胞免疫治疗的增效治疗方案，该治疗方案打破了长期以来认为化疗或放疗与体细胞免疫治疗不能联合使用的传统观点，为保护肿瘤患者免疫功能，提高疗效起到了积极的作用；3、率先提出了在肿瘤治疗过程中把不同的抗肿瘤免疫活性细胞交替使用的治疗方案，以防止一种抗肿瘤免疫效应细胞长期使用可能带来的免疫耐受，在临床上起到了较好的效果；4、率先提出把体细胞免疫治疗联合抗肿瘤的细胞因子、抗肿瘤抗体、生物分子靶向药物联合应用的增效治疗方案；5、率先提出在原发性肝癌手术或微创介入治疗后进行体细胞免疫治疗以抑制肿瘤复发和转移的个体化治疗模式，对有效抑制肝癌的复发和转移，提高原发性肝癌的疗效起到了较好的作用。目前，这些体细胞免疫治疗方案已在临床肿瘤治疗过程中得到广泛应用，为体细胞免疫治疗在临床肿瘤治疗过程中的规范化应用起到了重要作用，真正实现了基础研究的成果向临床应用的转化。
　　基于上述开拓性的工作，极大的推动了肿瘤体细胞免疫治疗在临床肿瘤中的应用，目前中山大学附属肿瘤医院生物治疗中心已成为“华南生物治疗基地”挂靠单位，这个基地将为生物治疗的临床应用、新项目的研发、人才培养和国际合作提供良好的平台，为推动我国肿瘤体细胞免疫治疗在规范化应用的基础上健康有序的发展将发挥重要作用。
2、肿瘤病因学的研究
　　主要致力于胃癌，肝癌和肾癌发病机制的研究，包括筛选与上述肿瘤密切相关的抑癌基因和癌基因，并进行相关功能的研究，同时结合临床，研究这些基因与临床疗效和预后之间的关系，为将来发展肿瘤新的有效治疗方法奠定实验基础。
3、近年来获得的科研基金项目
课题名称
课题类别
项目编号
研究年限
资助金额

靶向恶性实体肿瘤免疫细胞治疗新技术的研发及其临床转化路径的规范化建立


国家级国家重点研发计划项目


2018YFC**


2018—2020


1513万



精准靶向肿瘤相关抗原和T细胞免疫抑制相关受体及细胞免疫治疗新技术的建立


省部级广东省省计划项目重点项目


2017B


2017-2019


300万



Galectin-3通过β-Catenin信号通路调控血管生成促进肝癌转移分子机制的初步研究


国家级国家自然科学基金面上项目


**


2017-2021


55万



靶向肿瘤特异性抗原的精准免疫细胞治疗新技术研发和临床应用（附一牵头）


广州市健康医疗协同创新重大专项


5


2017-2020


175万



TESTIN基因抑制胃癌细胞转移分子机制的初步研究


国家级国家自然科学基金面上项目


**


2016-2019


68.4万



TESTIN基因抑制胃癌细胞转移分子机制的初步研究


省部级广东省省自然科学基金重点项目


S20**


2013-2016


20 万



IL-17细胞因子及Th17抗原特异性淋巴细胞抗食管癌作用及机制研究


国家自然科学基金


**


2012-2016


80万



靶向肾癌干细胞的特异性免疫治疗研究


广东省科技计划项目


2012A


2013-2015


20万



靶向肾癌干细胞的特异性免疫治疗研究


省部级广州市广州市计划项目


2013J**


2013-


2015


30 万元



肝癌干细胞特异性抗原筛选及诱导特异性CTL 研究


广东省科技计划项目


2011A


2012-2014


50万



胃癌中TESTIN基因失活机制及功能的初步研究


国家自然科学基金


**


2010-2012


32万



胃癌中TESTIN基因失活机制及功能的初步研究


广东省自然科学基金重点项目





2010-2012


20万



免疫治疗与体细胞治疗相关技术标准研究


卫生部


-2


2009-2012


265万



肝癌干细胞/DC疫苗增强抗肝癌免疫应答及机制研究


国家自然科学基金


u**


2008-2010


30万



RAK联合射频消融术治疗小肝癌的临床研究


与日本TAKARA公司合作研究




2008-2010



200万



抑制SOCS1基因表达联合OK-PSA刺激对树突状细胞抗肝癌免疫应答的影响及机制


国家自然科学基金


**


2006-2008


28万



胃癌D7S486位点附近抑癌基因的鉴定


高等学校博士点专项科研基金





2006-2008


6万



胃癌D7S486位点附近抑癌基因的鉴定


国家自然科学基金


**


2005-2007


21万



胃癌D7S486位点附近抑癌基因的鉴定


广东省自然科学基金重点项目


**


2005-2007


15万



胃癌D7S位点附近抑癌基因的鉴定


广州市科技攻关引导项目


2005-23-I0491


2005-2007


20万



自体DC与肾癌细胞融合疫苗治疗晚期肾癌患者的临床试验研究


广东省科技计划项目


2004B**


2005-2007


15万



自体DC/肾癌融合细胞疫苗治疗晚期肾癌的临床应用研究


广东省卫生厅重点项目


WSTJJ**


2005-2007



15万



自体DC/食道癌融合细胞疫苗治疗晚期食道癌的临床应用研究



广州市科技攻关引导项目



2004Z3-E0311



2004-2006



15万



胃癌7q32-qter区域的缺失及克隆研究


国家自然科学基金


**


2001-2003


16万




4、社会兼职
　　亚太医学生物免疫学会主任委员，中国细胞治疗质量控制和研究专业委员会主任委员，中国研究型医院学会生物治疗学专业委员会副主任委员，中国生物治疗临床应用专业委员会副主任委员，中国医药生物技术协会常务理事，中国细胞学会常务理事，广东省细胞生物学学会理事长，广东省抗癌协会生物治疗专业委员会主任委员，国家食品和药品监督管理局新药评审专家，国家华南肿瘤学重点实验室免疫与遗传研究课题组组长。美国《Cancer Letter》杂志编委,《癌症》杂志常务编委，国家自然基金和广东省自然基金重点项目评审专家。
5、个人荣誉及作品
获奖情况
（1）省科学技术进步二等奖；
（2）省教委科技进步奖一等奖；
（3）2008年首届广州新侨留学生回国创业贡献奖
专著
主编《肿瘤生物治疗基础与临床应用》，北京，科学出版社，2011年
副主编《个体化医学原则》专著（由人民卫生出版社2013年1月出版）；
获得专利
国家发明专利（专利号：ZL **.7） “一种分离纯化人肿瘤细胞的方法”
国家发明专利（专利号：ZL 2013 1 **.6） “用于刺激树突状细胞成熟的组合物以及方法 ”
国家发明专利（专利号ZL 2017 1 **.3） “DC-CIK细胞和抗PD-1抗体组合物及其用途”

发表论文
1. Pan QZ, Gu JM, Zhao JJ, Tang Y, Wang QJ, Zhu Q, Song MJ, Li YQ, He J, Chen SP, Weng DS, Xia JC(Corresponding). Retrospective analysis of the efficacy of cytokine-induced killer cell immunotherapy combined with first-line chemotherapy in patients with metastatic colorectal cancer. Clin Transl Immunology. 2020 Feb 19;9(2)
2. Pan QZ, Liu Q, Zhou YQ, Zhao JJ, Wang QJ, Li YQ, Tang Y, Gu JM, He J, Chen SP, Weng DS, Xia JC(Corresponding). CIK cell cytotoxicity is a predictive biomarker for CIK cell immunotherapy in postoperative patients with hepatocellular carcinoma. Cancer Immunol Immunother. 2020 Feb 14.
3. Huang XQ, Hao S, Zhou ZQ, Huang B, Fang JY, Tang Y, Zhang JH, Xia JC(Corresponding).The Roles of Ubiquitination Factor E4B (UBE4B) in the Postoperative Prognosis of Patients with Renal Cell Carcinoma and in Renal Tumor Cells Growth and Metastasis. Onco Targets Ther. 2020 Jan 8;13:185-197
4. Zhu Q, Zhong AL, Hu H, Zhao JJ, Weng DS, Tang Y, Pan QZ, Zhou ZQ, Song MJ, Yang JY, He JY, Liu Y, Li M, Hu WM, Yang CP, Xiang T, Chen MY, Ma G, Guo L, Xia JC(Corresponding). Acylglycerol kinase promotes tumour growth and metastasis via activating the PI3K/AKT/GSK3β signalling pathway in renal cell carcinoma.J Hematol Oncol. 2020 Jan 3;13(1):2.
5. Song M, Zhong A, Yang J, He J, Cheng S, Zeng J, Huang Y, Pan Q, Zhao J, Zhou Z, Zhu Q, Tang Y, Chen H, Yang C, Liu Y, Mo X, Weng D, Xia JC(Corresponding).Large-scale analyses identify a cluster of novel long noncoding RNAs as potential competitive endogenous RNAs in progression of hepatocellular carcinoma. Aging (Albany NY). 2019 Nov 23;11(22):10422-10453.
6. Zhou ZQ, Zhao JJ, Pan QZ, Chen CL, Liu Y, Tang Y, Zhu Q, Weng DS, Xia JC(Corresponding). PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer. J Immunother Cancer. 2019 Aug 27;7(1):228.
7. Liu Y, Zhao JJ, Zhou ZQ, Pan QZ, Zhu Q, Tang Y, Xia JC(Corresponding), Weng DS. IL-37 induces anti-tumor immunity by indirectly promoting dendritic cell recruitment and activation in hepatocellular carcinoma. Cancer Manag Res. 2019 Jul 18;11:6691-6702.
8. Zhu Q, Cai MY, Weng DS, Zhao JJ, Pan QZ, Wang QJ, Tang Y, He J, Li M, Xia JC(Corresponding). PD-L1 expression patterns in tumour cells and their association with CD8+ tumour infiltrating lymphocytes in clear cell renal cell carcinoma. J Cancer. 2019 Jan 29;10(5):1154-1161.
9. Wang DD, Chen YB, Zhao JJ, Zhang XF, Zhu GC, Weng DS, Pan K, Lv L, Pan QZ, Jiang SS, Wang LL, Xia JC(Corresponding). TES functions as a Mena-dependent tumor suppressor in gastric cancer carcinogenesis and metastasis. Cancer Commun (Lond). 2019 Feb 6;39(1):3.
10. Zhou Y, Chen CL, Jiang SW, Feng Y, Yuan L, Chen P, Zhang L, Huang S, Li J, Xia JC(Corresponding), Zheng M. Retrospective analysis of the efficacy of adjuvant CIK cell therapy in epithelial ovarian cancer patients who received postoperative chemotherapy. Oncoimmunology. 2018 Nov 11;8(2):
11. Zhao JJ, Zhou ZQ, Wang P, Chen CL, Liu Y, Pan QZ, Zhu Q, Tang Y, Weng DS, Xia JC(Corresponding). Orchestration of immune checkpoints in tumor immune contexture and their prognostic significance in esophageal squamous cell carcinoma. Cancer Manag Res. 2018 Nov 28;10:6457-6468.
12. Zhao JJ, Zhou S, Chen CL, Zhang HX, Zhou ZQ, Wu ZR, Liu Y, Pan QZ, Zhu Q, Tang Y, Xia JC(Corresponding), Weng DS. Clinical Effect of Adjuvant Cytokine-Induced Killer Cells Immunotherapy in Patients with Stage II-IVB Nasopharyngeal Carcinoma after Chemoradiotherapy: A propensity score analysis. J Cancer. 2018 Oct 20;9(22):4204-4214.
13. Zhu Q, Hu H, Tang LQ, You R, Zhao JJ, Weng DS, Pan QZ, Chen CL, Zhou ZQ, Tang Y, Xia JC(Corresponding). Weekly versus triweekly cisplatin plus intensity-modulated radiotherapy in locally advanced nasopharyngeal carcinoma: A propensity score analysis with a large cohort. J Cancer. 2018 Sep 8;9(19):3447-3455. .
14. Zhou ZQ, Zhao JJ, Chen CL, Liu Y, Zeng JX, Wu ZR, Tang Y, Zhu Q, Weng DS, Xia JC(Corresponding). HUS1 checkpoint clamp component (HUS1) is a potential tumor suppressor in primary hepatocellular carcinoma. Mol Carcinog. 2018 Sep 4.
15. Chen CL, Pan QZ, Weng DS, Xie CM, Zhao JJ, Chen MS, Peng RQ, Li DD, Wang Y, Tang Y, Wang QJ, Zhang ZL, Zhang XF, Jiang LJ, Zhou ZQ, Zhu Q, He J, Liu Y, Zhou FJ, Xia JC(Corresponding).Safety and activity of PD-1 blockade-activated DC-CIK cells in patients with advanced solid tumors.Oncoimmunology. 2018 Jan 10;7(4)
16. Chen CL, Wang Y, Huang CY, Zhou ZQ, Zhao JJ, Zhang XF, Pan QZ, Wu JX, Weng DS, Tang Y, Zhu Q, Yuan LP, Xia JC(Corresponding).IL-17 induces antitumor immunity by promoting beneficial neutrophil recruitment and activation in esophageal squamous cell carcinoma.Oncoimmunology. 2017 Sep 21;7(1)
17. Huang XQ, Zhou ZQ, Zhang XF, Chen CL, Tang Y, Zhu Q, Zhang JH, Xia JC(Corresponding).Overexpression of SMOC2 Attenuates the Tumorigenicity of Hepatocellular Carcinoma Cells and Is Associated With a Positive Postoperative Prognosis in Human Hepatocellular Carcinoma. J Cancer. 2017 Oct 17;8(18):3812-3827.
18. Huang XQ, Zhang XF, Xia JH, Chao J, Pan QZ, Zhao JJ, Zhou ZQ, Chen CL, Tang Y, Weng DS, Zhang JH, Xia JC(Corresponding). Tripartite motif-containing 3 (TRIM3) inhibits tumor growth and metastasis of liver cancer.Chin J Cancer. 2017 Sep 26;36(1):77
19. Zhu Q, Cai MY, Chen CL, Hu H, Lin HX, Li M, Weng DS, Zhao JJ, Guo L, Xia JC(Corresponding).Tumor cells PD-L1 expression as a favorable prognosis factor in nasopharyngeal carcinoma patients with pre-existing intratumor-infiltrating lymphocytes. Oncoimmunology. 2017 Apr 27;6(5)
20. Zhang XF, Weng DS, Pan K, Zhou ZQ, Pan QZ, Zhao JJ, Tang Y, Jiang SS, Chen CL, Li YQ, Zhang HX, Chang AE, Wicha MS, Zeng YX, Li Q, Xia JC(Corresponding).Dendritic-cell-based immunotherapy evokes potent anti-tumor immune responses in CD105+ human renal cancer stem cells.Mol Carcinog. 2017 Nov;56(11):2499-2511
21. Zhu Q, Hu H, Weng DS, Zhang XF, Chen CL, Zhou ZQ, Tang Y, Xia JC(Corresponding). Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC.BMC Cancer. 2017 Jun 12;17(1):412
22. Jiang SS, Jiang L, Weng DS, Li YF, Pan QZ, Zhao JJ, Tang Y, Zhou ZW, Xia JC(Corresponding). Immunization-based scores as independent prognostic predictors in soft tissue sarcoma patients. J Cancer. 2017 Feb 25;8(4):606-616.
23. Chen CL, Pan QZ, Zhao JJ, Wang Y, Li YQ, Wang QJ, Pan K, Weng DS, Jiang SS, Tang Y, Zhang XF, Zhang HX, Zhou ZQ, Zeng YX, Xia JC(Corresponding). PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma. Oncoimmunology. 2016 May 31;5(7)
24. Jiang SS, Weng DS, Jiang L, Zhang YJ, Pan K, Pan QZ, Chen CL, Zhao JJ, Zhang XF, Zhang HX, Tang Y, Zhou ZQ, Chen MS, Xia JC(Corresponding). The clinical significance of preoperative serum cholesterol and high-density lipoprotein-cholesterol levels in hepatocellular carcinoma. J Cancer. 2016 Mar 20;7(6):626-32.
25. Zhang XF, Pan K, Weng DS, Chen CL, Wang QJ, Zhao JJ, Pan QZ, Liu Q, Jiang SS, Li YQ, Zhang HX, Xia JC(Corresponding). Cytotoxic T lymphocyte antigen-4 expression in esophageal carcinoma: implications for prognosis. Oncotarget. 2016 May 3;7(18):26670-9
26. Xu L, Wang J, Kim Y, Shuang ZY, Zhang YJ, Lao XM, Li YQ, Chen MS, Pawlik TM, Xia JC(Corresponding), Li SP, Lau WY. A randomized controlled trial on patients with or without adjuvant autologous cytokine-induced killer cells after curative resection for hepatocellular carcinoma. Oncoimmunology. 2015 Oct 12; 5(3) :e**.
27. Pan QZ, Tang Y, Wang QJ, Li YQ, Zhang L, Li XD, Zhao JJ, Weng DS, Liu Q, Huang LX, He J, Chen SP, Ke ML, Zeng YX, Xia JC(Corresponding). Adjuvant cellular immunotherapy in patients with resected primary non-small cell lung cancer. Oncoimmunology. 2015 May 27;4(9)
28. Jiang SS, Tang Y, Zhang YJ, Weng DS, Zhou ZG, Pan K, Pan QZ, Wang QJ, Liu Q, He J, Zhao JJ, Li J, Chen MS, Chang AE, Li Q, Xia JC(Corresponding). A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma. Oncotarget 2015;6:41339-49.
29. Zhang XF, Pan QZ, Pan K, Weng DS, Wang QJ, Zhao JJ, He J, Liu Q, Wang DD, Jiang SS, Zheng HX, Lv L, Chen CL, Zhang HX, Xia JC(Corresponding). Expression and prognostic role of ubiquitination factor E4B in primary hepatocellular carcinoma. Mol Carcinog. 2015 Jan 3.
30. Pan QZ, Pan K, Wang QJ, Weng DS, Zhao JJ, Zheng HX, Zhang XF, Jiang SS, Lv L, Tang Y, Li YQ, He J, Liu Q, Chen CL, Zhang HX, Xia JC(Corresponding). Annexin A3 as a Potential Target for Immunotherapy of Liver Cancer Stem‐Like Cells. Stem Cells. 2014 Sep 29.
31. Jiang SS, Weng DS, Wang QJ, Pan K, Zhang YJ, Li YQ, Li JJ, Zhao JJ, He J, Lv L, Pan QZ, Xia JC(Corresponding). Galectin-3 is associated with a poor prognosis in primary hepatocellular carcinoma. J Transl Med. 2014 Sep 27;12(1):273.
32. Chao J, Zhang XF, Pan QZ, Zhao JJ, Jiang SS, Wang Y, Zhang JH, Xia JC(Corresponding). Decreased expression of TRIM3 is associated with poor prognosis in patients with primary hepatocellular carcinoma. Med Oncol. 2014 Aug;31(8):102.
33. Mai C, Zhao JJ, Tang XF, Wang W, Pan K, Pan QZ, Zhang XF, Jiang SS, Zhao BW, Li YF, Xia JC(Corresponding), Zhou ZW. Decreased ITIH5 expression is associated with poor prognosisin primary gastric cancer. Med Oncol.2014 Jul;31(7);53.
34. Pan K, Wang QJ, Liu Q, Zheng HX, Li YQ, Weng DS, Li JJ, Huang LX, He J, Chen SP, Ke ML, Zeng YX, Xia JC(Corresponding). The phenotype of ex vivo generated cytokine-induced killer cells is associated with overall survival in patients with cancer. Tumour Biol 2014;35(1): 701-7.
35. Wang H, Jiang S, Zhang Y, Pan K, Xia JC(Corresponding), Chen M. High expression of thymosin beta 10 predicts poor prognosis for hepatocellular carcinoma after hepatectomy. World J Surg Oncol 2014 Jul 18;12:226.
36. Zhao JJ, Pan QZ, Pan K, Weng DS, Wang QJ, Li JJ, Lv L, Wang DD, Zheng HX, Jiang SS, Zhang XF, Xia JC (Corresponding). Interleukin-37 Mediates the Antitumor Activity in Hepatocellular Carcinoma: Role for CD57+ NK Cells. Sci Rep. 2014 Jun 5;4:5177.
37. Zheng Y, Wang DD, Wang W, Pan K, Huang CY, Li YF, Wang QJ, Yuan SQ, Jiang SS, Qiu HB, Chen YM, Zhang XF, Zhao BW, Mai C, Xia JC (Corresponding), Zhou ZW. Reduced expression of uroplakin 1A is associated with the poor prognosis of gastric adenocarcinoma patients. PLoS One. 2014 Apr 3;9(4):e93073.
38. Pan K, Guan XX, Li YQ, Zhao JJ, Li JJ, Qiu HJ, Weng DS, Wang QJ, Liu Q, Huang LX, He J, Chen SP, Ke ML, Zeng YX, Xia JC (Corresponding). Clinical activity of adjuvant cytokine-induced killer cell (CIK) immunotherapy in patients with post-mastectomy triple-negative breast cancer patients. Clin Cancer Res. 2014 Jun 1;20(11):3003-11.
39. Keshari RP, Wang W, Zhang Y, Wang DD, Li YF, Yuan SQ, Qiu HB, Huang CY, Chen YM, Xia JC (Corresponding), Zhou ZW. Decreased Expression of the GATA3 Gene Is Associated with Poor Prognosis in Primary Gastric Adenocarcinoma. PLoS One. 2014 Feb 4;9(2):e87195
40. Pan K, Lv L, Zheng HX, Zhao JJ, Pan QZ, Li JJ, Weng DS, Wang DD, Jiang SS, Chang AE, Li Q, Xia JC(Corresponding). OK-432 synergizes with IFN-γ to confer dendritic cells with enhanced antitumor immunity. Immunol Cell Biol. 2014 Mar;92(3):263-74.
41. Wang SH, Lu L, Fan Y, Wicha MS, Cao Z, Chang AE, Xia JC, Baker JR Jr, Li Q.Characterization of a novel transgenic mouse tumor model for targeting HER2+ cancer stem cells. Int J Biol Sci. 2013 Dec 6;10(1):25-32.
42. Pan QZ, Pan K, Weng DS, Zhao JJ, Zhang XF, Wang DD, Lv L, Jiang SS, Zheng HX, Xia JC(Corresponding). Annexin A3 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma. Mol Carcinog. 2013 Dec 23.
43. Yang XB, Zhao JJ, Huang CY, Wang QJ, Pan K, Wang DD, Pan QZ, Jiang SS, Lv L, Gao X, Chen HW, Yao JQ, Zhi M, Xia JC (Corresponding). Decreased Expression of the FOXO3a Gene Is Associated with Poor Prognosis in Primary Gastric Adenocarcinoma Patients. PLoS One. 2013 Oct 230;8(10): e78158
44. Pan QZ, Pan K, Zhao JJ, Chen JG, Li JJ, Lv L, Wang DD, Zheng HX, Jiang SS, Zhang XF, Xia JC (Corresponding). Decreased expression of interleukin-36α correlates with poor prognosis in hepatocellular carcinoma. Cancer Immunol Immunother. 2013 Sep 6.
45. Lu L, Pan K, Zheng HX, Li JJ, Qiu HJ, Zhao JJ, Weng DS, Pan QZ, Wang DD, Jiang SS, Chang AE, Li Q, Xia JC (Corresponding). IL-17A promotes immune cell recruitment in human esophageal cancers and the infiltrating dendritic cells represent a positive prognostic marker for patient survival. J Immunother. 2013 Oct;36(8):451-8.
46. Huang CY, Zhao JJ, Lv L, Chen YB, Li YF, Jiang SS, Wang W, Pan K, Zheng Y, Zhao BW, Wang DD, Chen YM, Yang L, Zhou ZW, Xia JC (Corresponding). Decreased Expression of AZGP1 Is Associated with Poor Prognosis in Primary Gastric Cancer. PLoS One. 2013 Jul 23;8(7):e69155.
47. Pan K, Li YQ, Wang W, Xu L, Zhang YJ, Zheng HX, Zhao JJ, Qiu HJ, Weng DS, Li JJ, Wang QJ, Huang LX, He J, Chen SP, Ke ML, Wu PH, Chen MS, Li SP, Xia JC (Corresponding), Zeng YX. The Efficacy of Cytokine-Induced Killer Cell Infusion as an Adjuvant Therapy for Postoperative Hepatocellular Carcinoma Patients. Ann Surg Oncol. 2013 Jul 27.
48. Huang ZM, Li W, Li S, Gao F, Zhou QM, Wu FM, He N, Pan CC, Xia JC, Wu PH, Zhao M. Cytokine-induced killer cells in combination with transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma patients. J Immunother. 2013 Jun;36(5):287-93.
49. Zhang F, Sun XF, Li YQ, Zhen ZJ, Zheng HX, Zhu J, Wang QJ, Lu SY, He J, Wang J, Pan K, Cai RQ, Chen Y, Weng DS, Sun FF, Xia JC (Corresponding). Safety of in vitro amplified HLA-haploidentical donor immune cell infusions for childhood malignancies. Chin J Cancer. 2013 May 27. doi: 10.5732 / cjc.012.10298.
50. Zhao JJ, Pan K, Wang QJ, Xu ZD, Weng DS, Li JJ, Li YQ, Xia JC (Corresponding). Effect of anti-asthma Chinese medicine Chuankezhi on the anti-tumor activity of cytokine-induced killer cells. Chin J Cancer. 2013 Mar 8. doi: 10.5732/cjc.012.10249.
51. Huang CY, Chen YM, Zhao JJ, Chen YB, Jiang SS, Yan SM, Zhao BW, Pan K, Wang DD, Lv L, Li YF, Wang W, Zhou ZW, Xia JC (Corresponding). Decreased expression of transcription elongation factor a-like 7 is associated with gastric adenocarcinoma prognosis. PLoS One. 2013;8(1):e54671.
52. Li JJ, Shan HB, Xu GL, He LJ, Xia JC. Submucosal saline solution injection combined with endosonography for distinguishing between stages T1a and T1b of early esophageal cancer. Gastrointest Endosc. 2013 Jan;77(1):159-60.
53. Li JJ, Pan K, Gu MF, Chen MS, Zhao JJ, Wang H, Liang XT, Sun JC, Xia JC (Corresponding). Prognostic value of soluble MICA levels in the serum of patients with advanced hepatocellular carcinoma. Chin J Cancer. 2013 Mar;32(3):141-8.
54. Li YF, Wang DD, Zhao BW, Wang W, Huang CY, Chen YM, Zheng Y, Keshari RP, Xia JC (Corresponding), Zhou ZW. High Level of COP1 Expression is Associated with Poor Prognosis in Primary Gastric Cancer. Int J Biol Sci. 2012;8(8):1168-77.
55. Li YF, Wang DD, Zhao BW, Wang W, Yuan SQ, Huang CY, Chen YM, Zheng Y, Keshari RP, Xia JC (Corresponding), Zhou ZW. Poor prognosis of gastric adenocarcinoma with decreased expression of AHRR. PLoS One. 2012;7(8):e43555.
56. Wang DD, Chen YY, Pan K, Wang W, Chen SP, Chen JG, ZhaoJJ, Lv L, Pan QZ, Li YQ, Wang QJ, Huang LX, Ke ML, He J, Xia JC (Corresponding). Decreased Expression of the ARID1A Gene Is Associated with Poor Prognosis in Primary Gastric Cancer. PLoS One. 2012; 7(7): e40364
57. Zhao JJ, Pan K, Wang W, Chen JG, Wu YH, Lv L, Li JJ, Chen YB, Wang DD, Pan QZ, Li XD, Xia JC (Corresponding). The prognostic value of tumor-infiltrating neutrophils in gastric adenocarcinoma after resection. PLoS One. 2012;7(3):e33655.
58. Li JJ, Gu MF, Pan K, Liu LZ, Zhang H, Shen WX, Xia JC (Corresponding). Autologous Cytokine-Induced Killer Cell Transfusion in Combination with Gemcitabine plus Cisplatin Regimen Chemotherapy for Metastatic Nasopharyngeal Carcinoma. J Immunotherapy. 2012 Feb-Mar;35(2):189-95.
59. Pan K, Liang XT, Zhang HK, Zhao JJ, Wang DD, Li JJ, Lian Q, Chang AE, Li Q, Xia JC (Corresponding).. Characterization of BIN1 as a potential tumor suppressor and prognostic marker in hepatocellular carcinoma. Mol Med. 2012 18:507-18.
60. Chen Y, Pan K, Li S, Xia J (Corresponding), Wang W, Chen J, Zhao J, Lü L, Wang D, Pan Q, Wang Q, Li Y, He J, Li Q. Decreased expression of V-set and immunoglobulin domain containing 1 (VSIG1) is associated with poor prognosis in primary gastric cancer. J Surg Oncol. 2012 Sep 1;106(3):286-93.
61. Zhao JJ, Pan K, Li JJ, Chen YB, Chen JG, Lv L, Wang DD, Pan QZ, Chen MS, Xia JC (Corresponding). Identification of LZAP as a New Candidate Tumor Suppressor in Hepatocellular Carcinoma. PLoS One. 2011; 6(10): e26608.
62. Wang W, Lv L, Pan K, Zhang Y, Zhao JJ, Chen JG, Chen YB, Li YQ, Wang QJ, He J, Chen SP, Xia JC (Corresponding). Reduced expression of transcription factor AP-2α is associated with gastric adenocarcinoma prognosis. PLoS One. 2011; 6(9): e24897.
63. Lv L, Pan K, Li XD, She KL, Zhao JJ, Wang W, Chen JG, Chen YB, Yun JP, Xia JC (Corresponding). The accumulation and prognosis value of tumor infiltrating IL-17 producing cells in esophageal squamous cell carcinoma. PLoS One. 2011; 6(3): e18219.
64. Liang XT, Pan K, Chen MS, Li JJ, Wang H, Zhao JJ, Sun JC, Chen YB, Ma HQ, Wang QJ, Xia JC (Corresponding). Decreased expression of XPO4 is associated with poor prognosis in hepatocellular carcinoma. J Gastroenterol Hepatol. 2011; 26(3): 544-9
65. Ma H, Liang X, Chen Y, Pan K, Sun J, Wang H, Wang Q, Li Y, Zhao J, Li J, Chen M, Xia J (Corresponding). Decreased expression of BATF2 is associated with a poor prognosis in hepatocellular carcinoma. Int J Cancer. 2011; 128(4): 771-7.
66. Chen JG, Xia JC (Corresponding), Liang XT, Pan K, Wang W, Lv L, Zhao JJ, Wang QJ, Li YQ, Chen SP, He J, Huang LX, Ke ML, Chen YB, Ma HQ, Zeng ZW, Zhou ZW, Chang AE, Li Q. Intratumoral Expression of IL-17 and Its Prognostic Role in Gastric Adenocarcinoma Patients. Int J Biol Sci. 2011; 7(1): 53-60.
67. Ma H, Weng D, Chen Y, Huang W, Pan K, Wang H, Sun J, Wang Q, Zhou Z, Wang H, Xia J (Corresponding). Extensive analysis of D7S486 in primary gastric cancer supports TESTIN as a candidate tumor suppressor gene. Mol Cancer. 2010; 9:190.
68. Pan K, Zhao JJ, Wang H, Li JJ, Liang XT, Sun JC, Chen YB, Ma HQ, Liu Q, Xia JC (Corresponding). Comparative analysis of cytotoxic T lymphocyte response induced by dendritic cells loaded with hepatocellular carcinoma -derived RNA or cell lysate. Int J Biol Sci. 2010; 6(7): 639-48.
69. Sun JC, Liang XT, Pan K, Wang H, Zhao JJ, Li JJ, Ma HQ, Chen YB, Xia JC (Corresponding). High expression level of EDIL3 in HCC predicts poor prognosis of HCC patients. World J Gastroenterol. 2010; 16(36): 4611-5.
70. Wang QJ, Wang H, Pan K, Li YQ, Huang LX, Chen SP, He J, Ke ML, Zhao JJ, Li JJ, Sun JC, Liang XT, Ma HQ, Chen YB, Xia JC (Corresponding). Comparative study on anti-tumor immune response of autologous cytokine-induced killer (CIK) cells, dendritic cells-CIK (DC-CIK), and semi-allogeneic DC-CIK. Chin J Cancer. 2010; 29(7): 641-8.
71. Sun JC, Pan K, Chen MS, Wang QJ, Wang H, Ma HQ, Li YQ, Liang XT, Li JJ, Zhao JJ, Chen YB, Pang XH, Liu WL, Cao Y, Guan XY, Lian QZ, Xia JC (Corresponding). Dendritic cells-mediated CTLs targeting hepatocellular carcinoma stem cells. Cancer Biol Ther. 2010; 10(4): 368-75.
72. Ma H, Zhang Y, Wang Q, Li Y, He J, Wang H, Sun J, Pan K, Chen M, Xia J (Corresponding). Therapeutic safety and effects of adjuvant autologous RetroNectin activated killer cell immunotherapy for patients with primary hepatocellular carcinoma after radiofrequency ablation. Cancer Biol Ther. 2010; 9(11): 903-7.
73. Zhang H, Ma H, Wang Q, Chen M, Weng D, Wang H, Zhou J, Li Y, Sun J, Chen Y, Liang X, Zhao J, Pan K, Wang H, Xia J (Corresponding). Analysis of loss of heterozygosity on chromosome 4q in hepatocellular carcinoma using high-throughput SNP array. Oncol Rep. 2010; 23(2): 445-55.
74. Zhou J, Weng D, Zhou F, Pan K, Song H, Wang Q, Wang H, Wang H, Li Y, Huang L, Zhang H, Huang W, Xia JC (Corresponding). Patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells elicit anti-tumor activity: in vitro results and clinical responses. Cancer Immunol. Immunother. 2009; 58(10): 1587-97.
75. Pan K, Wang H, Liu W, Zhang H, Zhou J, Li J, Weng D, Huang W, Sun J, Liang X, Xia JC (Corresponding). The pivotal role of p38 and NF-κB signal pathways in the maturation of human monocyte-derived dendritic cells stimulated by streptococcal agent OK-432. Immunobiology 2009; 214(5): 350-358.
76. Zhang HK, Pan K, Wang H, Weng DS, Song HF, Zhou J, Huang W, Li JJ, Chen MS, Xia JC (Corresponding). Decreased Expression of Ing2 Gene and Its Clinicopathological Significance in Hepatocellular Carcinoma. Cancer Lett. 2008; 261(2): 183-192.
77. Weng DS, Zhou J, Zhou QM, Zhao M, Wang QJ, Huang LX, Li YQ, Chen SP, Wu PH, Xia JC (Corresponding). Minimally Invasive Treatment Combined with Cytokine-Induced Killer Cells Therapy Lower the Short-Term Recurrence Rates of Hepatocellular Carcinomas. J Immunother. 2008; 31(1): 63-71.
78. Ma HQ, Liang XT, Zhao JJ, Wang H, Sun JC, Chen YB, Pan K, Xia JC (Corresponding). Decreased expression of Neurensin-2 correlates with poor prognosis in hepatocellular carcinoma. World J Gastroenterol. 2009; 15(38): 4844-8.
79. Wang H, Pan K, Zhang HK, Weng DS, Zhou J, Li JJ, Huang W, Song HF, Chen MS, Xia JC (Corresponding). Increased Polycomb-Group Oncogene Bmi-1 Expression Correlates with Poor Prognosis in Hepatocellular Carcinoma. J Cancer Res Clin Oncol. 2008; 134(5): 535-541.
80. Pan K, Wang H, Chen MS, Zhang HK, Weng DS, Zhou J, Huang W, Li JJ, Song HF, Xia JC (Corresponding). Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2008; 134(11):1247-1253
81. Weng DS, Li JT, Mai SJ, Pan ZZ, Feng BJ, Feng QS, Huang LX, Wang QJ, Li YQ, Yu XJ, Chen SP, He J, Xia JC (corresponding). Identification of a new target region on the long arm of chromosome 7 in gastric carcinoma by loss of heterozygosity. World J Gastroenterol. 2006; 12(15): 2437-2440.
82. Xia JC, Weng DS, Li JT, Qin HD, Mai SJ, Feng BJ, Fan Q, Feng QS, Huang LX, Yu XJ, Pan ZZ, Li YQ, Wang QJ, Zhan YQ, Chen SP, He J, Huang WL, Wu PH, Zeng YX. Loss of heterozygosity analysis of a candidate gastric carcinoma tumor suppressor locus at 7q31. Cancer Genet Cytogenet. 2006; 166(2): 166-172.
83. Tanaka Y, Koido S, Xia JC （co-firster author）, Ohana M, Liu C, Cote GM, Sawyer DB, Calderwood S, Gong J. Development of Antigen-Specific CD8+ Cytotoxic T Lymphocytes in MHC Class I-Deficient Mice through CD4 to CD8 Conversion. J Immunol. 2004; 172: 7848-7858.
84. Xia JC, Tanaka Y, Koido S, Liu C, Mukherjee P, Gendler SJ, Gong J. Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells. J Immunol. 2003; 170 (4): 1980-1986.

更新日期：2020年2月27日